Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview-Reference-Cited by-同舟云学术

Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview

Published:2022-09-01 Issue:8 Volume:22 Page:1163-1170
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Igarashi Ataru¹²^ORCID,Ikeda Shunya³

Affiliation:

1. Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, Yokohama, Japan

2. Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

3. Department of Public Health, School of Medicine, International University of Health and Welfare, Chiba, Japan

Funder

Eisai Co., Ltd and Biogen Japan Ltd

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2022.2118113

Reference44 articles.

1. Dementia [Internet]. Geneva (Switzerland): World Health Organization; 2021 [cited 2022 Mar 11]. Available from: https://www.who.int/news-room/fact-sheets/detail/dementia

2. Ninomiya T Research on future projection of the population of the elderly with dementia in Japan. Tokyo (Japan): Ministry of Health, Labour and Welfare; 2015. Japanese.

3. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

4. Alzheimer's disease

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship of the Japanese Old Stories Cognitive Scale With the Revised Hasegawa Cognitive Scale and Mini-Mental State Examination;Journal of Applied Gerontology;2024-04-17

2. Evaluation of the beneficial effects of ETAS® on normal aging or mild cognitive impairment subjects: A pilot randomized controlled trial;Journal of Pharmacy & Pharmacognosy Research;2024-01-01

3. Predicting the Societal Value of Lecanemab in Early Alzheimer’s Disease in Japan: A Patient-Level Simulation;Neurology and Therapy;2023-05-15